Biotech's drug for Alzheimer's disease shows promise

07/30/2008 | Reuters

Rember, an Alzheimer's drug from biotechnology firm TauRX, significantly improved cognition and memory in patients with a moderate form of the disease, a Phase II study found. The experimental treatment works by dissolving tangles of the tau protein that are known to play a role in dementia. Other experts cautioned that it is too early to make conclusions from the study findings.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA